Malignant cells proliferate within the tissue of origin and some of them reach the circulation and spread via blood and lymph vessels. In a further step of tumor progression, these cells extravasate and seed into other t i~s u e s .~.~ Adhesive interactions between neoplastic cells, endothelial cells, and extracellular matrix (ECM) proteins are crucial for these sequential events to O C C U~.~.~ Expression of adhesion molecules of the Ig superfamily, of the integrin family, of the selectin family, and of the "lymphocyte homing receptor," CD44, has been investigated in lymphoproliferative However, a complete pattern of adhesion molecule expression in lymphoid malignancy has not yet emerged, and conflicting data on the prognostic significance of these phenotypic features have been reported. '',I6 B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disorder with a high degree of biologic heter~geneity.".~~ This lymphoid malignancy originates from a CD5+ normal B-cell counterpart that may represent a distinct subset of B However, in less than 10% of the cases, B-CLL cells do not express CD5.19-2' Other phenotypic features may be heterogeneous among B-CLL cases, such as expression of pz integrin molecules (CD I I b/CD18 and CD1 lc/CD18) found on myelomonocytic cells and on hairy cell leukemia (HCL) ~e l l s .~~,~~ Expression of CD 1 1 b/CD 18 has been associated with the ability of B-CLL cells to produce interleukin-1 ,23 whereas expression of CD1 lc/CD I8 appears to define a B-CLL variant with distinctive clinical feature^.^^.^^ Further phenotypic heterogeneity of B-CLL cells is due to maturational differences among malignant clones and to intraclonal maturation, as shown by ultrastructural and cytochemical analyses. 27 Clinical heterogeneity of B-CLL is also well defined and prognosis is often unpredi~table.''.~~ Many patients do not require treatment and are unlikely to die of leukemia. In contrast, other patients present with rapidly progressive disease and have a median survival of less than 2 years. So far, ; of the PI, p2, and p3 integrin family; of the selectin family (L-selectin/ Leu8); and of CD44 have been analyzed by immunofluorescence and flow cytometry (see the l i t e r a t~r e~~.~~ for reviews on these molecules). Expression of adhesion molecules has allowed distinction of phenotypically diverse groups of patients and clinical differences have emerged among some of these groups.
OST LYMPHOPROLIFERATIVE disorders are M monoclonal expansions of B or T cells at different stages of maturation that evolve as leukemia or lymphoma. ' Malignant cells proliferate within the tissue of origin and some of them reach the circulation and spread via blood and lymph vessels. In a further step of tumor progression, these cells extravasate and seed into other t i~s u e s .~.~ Adhesive interactions between neoplastic cells, endothelial cells, and extracellular matrix (ECM) proteins are crucial for these sequential events to O C C U~.~.~ Expression of adhesion molecules of the Ig superfamily, of the integrin family, of the selectin family, and of the "lymphocyte homing receptor," CD44, has been investigated in lymphoproliferative However, a complete pattern of adhesion molecule expression in lymphoid malignancy has not yet emerged, and conflicting data on the prognostic significance of these phenotypic features have been reported. '',I6 B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disorder with a high degree of biologic heter~geneity.".~~ This lymphoid malignancy originates from a CD5+ normal B-cell counterpart that may represent a distinct subset of B However, in less than 10% of the cases, B-CLL cells do not express CD5.19-2' Other phenotypic features may be heterogeneous among B-CLL cases, such as expression of pz integrin molecules (CD I I b/CD18 and CD1 lc/CD18) found on myelomonocytic cells and on hairy cell leukemia (HCL) ~e l l s .~~,~~ Expression of CD 1 1 b/CD 18 has been associated with the ability of B-CLL cells to produce interleukin-1 ,23 whereas expression of CD1 lc/CD I8 appears to define a B-CLL variant with distinctive clinical feature^.^^.^^ Further phenotypic heterogeneity of B-CLL cells is due to maturational differences among malignant clones and to intraclonal maturation, as shown by ultrastructural and cytochemical analyses. 27 Clinical heterogeneity of B-CLL is also well defined and prognosis is often unpredi~table.''.~~ Many patients do not require treatment and are unlikely to die of leukemia. In contrast, other patients present with rapidly progressive disease and have a median survival of less than 2 years. So far, a clear correlation between the surface antigenic phenotype of leukemic cells and the clinical behavior has not been defined.
In the present study, we have investigated the expression of a variety of adhesion molecules on cells from 74 B-CLL patients. Surface molecules of the Ig superfamily (CD54/intercellular adhesion molecule-1 [ICAM-I ] and CD58/lymphocyte function-associated antigen 3 [LFA-3]); of the PI, p2, and p3 integrin family; of the selectin family (L-selectin/ Leu8); and of CD44 have been analyzed by immunofluorescence and flow cytometry (see the l i t e r a t~r e~~.~~ for reviews on these molecules). Expression of adhesion molecules has allowed distinction of phenotypically diverse groups of patients and clinical differences have emerged among some of these groups.
MATERIALS AND METHODS
Patients. Seventy-four patients were evaluated in our Division from September 1990 through December 199 I. The mean age of the patients was 62 years, with a range between 41 and 85 years. There was one 19-year-old female. The male to female ratio was 40 to 34.
B-CLL was diagnosed according to generally accepted criteria that included peripheral blood lymphocytosis greater than 5,OOO/pL and bone marrow lymphocytosis greater than 3070. ' At the time of study, 63 of 74 patients had never been treated. However, at a later time, 23 of the 63 patients had to start treatment with chlorambucil (CHL) and prednisone (PDN). Eleven patients were studied when receiving the CHL plus PDN regimen.
As of June 1992, I 1 patients are deceased, 9 of disease progression, 1 due to a second neoplasia, and 1 from myocardial infarction.
Clinical evaluation of the patients included staging according to Rai et aP5 and Binet et al,36 peripheral blood lymphocytosis, evaluation of liver, spleen, and lymph node enlargement (aided by computed axial tomography [CAT] and echotomography), and lymphocyte doubling time (LDT). 37 The pattern of bone marrow infiltrati~n~~ was evaluated in bone marrow biopsies of 52 of 74 patients. Biopsy was not performed in 22 patients due to advanced age, cardiovascular risk factor, or refusal of informed consent.
Mononuclear cells were isolated from heparinized peripheral blood samples by Ficoll-Hypaque density gradient centrifugation. When, in addition to peripheral blood samples, bone marrow aspirates were also available (7 of 74 patients), single-cell suspensions of bone marrow cells were centrifuged on Ficoll-Hypaque density gradients to recover mononuclear cells. Freshly isolated mononuclear cells were used for immunophenotypic analyses. Further immunophenotypic and biochemical studies were performed using frozen cell aliquots stored in liquid nitrogen.
Cells were incubated with mouse monoclonal antibodies (MoAbs) to a variety of surface molecules (as indicated in Table l), followed by affinity-purified, fluorescein isothiocyanate (FITC)-labeled goat antimouse Ig (Southern Biotechnology Associates, Birmingham, AL). In other experiments, biotinylated MoAbs were used, followed by FITC-streptavidin.
Two-color immunofluorescence analyses were performed using FITC-labeled and phycoerythrin (PE)-labeled mouse MoAbs ( Table  1) . Controls were provided by cells incubated directly with the secondary reagent, omitting the primary reagent, and by cells incubated with an unrelated MoAb of an isotype identical to that of the test MoAb (anti-CD62, IgG1; anti-CD10, IgG2a; anti-CD69, IgGZb), followed by the labeled secondary reagent ( Table 1) . These antibodies were used as negative controls.
Cells were analyzed by one-color or two-color fluorescence using a FACScan flow cytometer (Becton Dickinson, San Jose, CA) and setting gates on the lymphocyte populations. Analysis by two-color fluorescence was restricted to those markers that appeared equivocal as for their attribution to B-CLL cells or to residual T cells. However, this was seldom the case because in the majority of the patients (53 of 74) the percentage of leukemic cells was greater than 70%.
B-CLL cells were washed twice in cold phosphate-buffered saline (PBS) and resuspended in PBS with IO mmol/L glucose. Surface proteins were labeled with sulfosuccinimidyl 6-(biotinamido) hexanoate (NHS-LC-Biotin; Pierce, Rockford, IL).39 Ten million cells and 2.5 mg of biotin were used per experiment. Labeled cells were lysed with 10 mmol/L Tris, 150 mmol/L NaCI, and 1% NP-40, pH 7.5, containing protease inhibitors. Lysates were centrifuged for IO minutes at 10,OOOg. The supematant was precleared twice with 50 fiL of beads coated with antimouse IgG (Calbiochem, San Diego, CA). Beads were sedimented by centrifugation for 2 minutes at 10,OOOg and the supernatant was used for immunoprecipitation. Ten micrograms of monoclonal anti-CD61 MoAb (Immunotech) was added to each sample and incubated overnight at 4°C. Fifty microliters of bead-immobilized antimouse IgG was added to each tube and the samples were rotated for I hour at 4°C. times with cold lysis buffer and twice with 10 mmol/L Tris, 2 mmol/ L ECTA, 0. I % sodium dodecyl sulfate (SDS), pH 7.5. followed by elution with sample buffer. Eluates were run on 7.5% polyacrylamide gel under nonreducing conditions. Polypeptides separated by SDSpolyacrylamide gel electrophoresis (SDS-PAGE) were transferred to nitrocellulose. The filter was saturated for I hour with 50 mmol/L Tris, 150 mmol/L NaCI, 5% nonfat dry milk, pH 7.5, and then incubated overnight with alkaline phosphatase-conjugated avidin (BioRad, Richmond, CA). Bands were visualized using 5-bromo-4-chloro-indoxyl phosphate and nitroblue tetrazolium (Sigma, St Louis, MO) as substrate. 40 Each single clinical and phenotypic parameter has been matched with all of the others using the statistical technique of cross tabs. We used the Pearson x2 test (SPSS/PC) to define the significance of each cross and analyzed the percentages in each tab. When the probability value was less than .05, the hypothesis that the two examined variables are independent was rejected.
The Student's t-test was used to evaluate statistical differences in the mean lymphocyte counts among various phenotypic groups.
Statistical analweJ.

RESULTS
Seventy-four B-CLL patients were considered in this study.
In all of the samples, leukemic cells were enumerated via the expression of HLA-DR and residual T cells were identified through the expression of surface CD3 molecules.
In 52 of 74 patients, we determined percentages of HLA-DR' B-CLL cells greater than 70%. In the remaining patients, these percentages ranged from 50% t o 70%. In the majority of the patients (67 of 74), residual T cells were less than 20%. Consequently, the threshold of positivity for each marker was set at greater than 20%. In the 7 cases that had greater than 20% T cells, the phenotypes of leukemic cells were assessed by two were positive for all three of the p chains (Table 2 and Fig   1) .
Due to the sensitivity threshold of the indirect immunofluorescence technique routinely used to determine integrin /3 chain expression and to assess whether a negative result could indicate absence of a given p chain or its expression at a very low density, we tested different detection systems. In one approach, labeled antimouse Ig isotype (IgG2a and IgGI) antibodies were used as secondary reagents to detect chain expression. Fluorescence-activated cell sorter (FACS) analyses did not show differences in fluorescence intensity when these reagents were compared with secondary antitotal mouse Ig antibodies (data not shown). In contrast, significant differences in / 3 chain expression on B-CLL cells were shown when results from indirect immunofluorescence assays were compared with those obtained using biotinylated primary mouse MoAb followed by fluorescein-labeled streptavidin (Fig 2) .
While confirming previous results showing that, in most B-CLL cases, PI and p2 integrin chains are expressed on the surface of malignant B ~e l l s ,~~~~~-' " ' we observed that, in 12 of 74 patients (Table 2) , B-CLL cells also expressed surface p3
chains detectable by indirect immunofluorescence (Fig 1) .
Lymphocytes from 4 patients, 3 positive for surface p3 chains and 1 negative by FACS analysis, were labeled with biotin and immunoprecipitated with anti-CD6 1 MoAb followed by SDS-PAGE. A band of 90 Kd was present in the three cases whose cells expressed p3 chains detectable by immunofluorescence. No band was detected in the p; case (Fig 3) . An unidentified band of approximately 68 Kd found in two cases (lanes B and C in Fig 3 ) could be a proteolytic fragment of the 90-Kd polypeptide. In all of the cases we also found coexpression of surface PI and p2 chains. Table 2 ). In all of the cases, p2 chains were coexpressed with aL chains to form the CD1 la/CD18 (LFA-1) heterodimer; aM (CD1 lb, OKMI/MacI) and ax (CD1 IC, LeuM5) were detected, respectively. on p i cells from 1 of 41 and 14 of 41 patients. Cells from the latter group of patients were analyzed by two-color direct immunofluorescence to determine percentages of leukemic (HLA-DR') cells also expressing LeuM5. Figure 4 shows three representative cases in which HLA-DR+ cells also expressed LeuM5 at variable proportions. Notably, p3 was found in 6 of 14 cases in which cells were LeuM5'. The difference in p3 expression on cells from LeuM5' versus LeuM5-cases was highly significant (P = .0027).
In seven cases in which blood and bone marrow samples were simultaneously available, we found that expression of integrin @ chains was identical in cells from five patients. PI chains were detectable on blood but not on bone marrow B-CLL cells in one case. The opposite occurred in another case.
L-selectin (Leu8) was detectable on the surface of B-CLL cells in 2 1 of 74 cases. Variable proportions of leukemic cells were positive for Lselectin in the various cases (Fig 5) . We did not find significant differences in the frequency of L-selectin-positive cases among the patient groups expressing different sets of p chains.
In one of seven cases in which blood and marrow samples
Expression ofL-selectin on B-CLL cells.
were tested simultaneously, L-selectin was detected on blood but not on bone marrow cells. No difference was observed in the remaining cases.
CD44 was detectable on B-CLL cells from all patients but one. The intensity of CD44 expression on leukemic cells was compared with that of residual T cells by two-color immunofluorescence. As shown in Fig 6, CD44 was expressed on CD3' cells at higher density than on HLA-DR+ (€3-CLL) cells. However, in several cases, both cell types expressed CD44 at the same density. This allowed us to distinguish three groups of patients according to high (16 of 73), intermediate ( 
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did or did not express the various types of adhesive receptors at detectable levels. All of the phenotypic differences were related to clinical parameters, namely, stage of disease according to Rai and Binet. LDT, peripheral blood lymphocytosis. splenomegaly. hepatomegaly, nodal involvement, bone marrow infiltration pattern, and therapy requirement.
90-
A B C D Patients whose cells expressed CD58 were more frequently assigned to the Rai 3 and 4 and Binet B and C stages (P = .038) and exhibited a higher incidence of splenomegaly (P = . O B ) . As for CD54. we did not find significant correlations with the evaluated clinical parameters. Several correlations between B-CLL cell phenotype and clinical features were found when integrin p chain expression was analyzed (Table 2 ). Cases lacking P I , p2, and & chain expression had a significantly lower incidence ofsplenomegaly (P = .004). When cases lacking all of the analyzed p chains were compared with those expressing all three p chains, it was found that the former had a significantly lower incidence of diffuse bone marrow infiltration (P = .044) and oftherapy requirement (P = .027) ( Table 2 ). Among the three groups.
p chain-negative cases had the lowest peripheral blood lymphocytosis. but these data were not statistically significant (P = .08).
In view of the possibility that (Y& (LeuM5) expression distinguishes a subset of patients with a more aggressive disease ~o u r s e .~~.~~ or variants of chronic lymphoproliferative disorders?5 we examined the clinical features of 14 LeuM5' versus 60 LeuM5-cases (Table 3) . Patients in the former group presented with a significantly higher lymphocytosis (P = .021) and need for therapy (P = .006).
L-selectin was detected on cells from 21 of 74 cases. No significant correlation has been observed between clinical parameters and Leu8 expression.
As for the variable intensity ofCD44 expression on B-CLL cells. the only clinical difference among the three groups was that between CD44'"w and CD44high cases. A significantly increased incidence of diffuse bone marrow infiltration was found in the latter group (P = .O 12). largely rests upon the detection system that is used. Therefore, negativity or positivity for surface adhesion molecules is of relative value, and is probably attributable to the surface density of any given molecule rather than to its presence or absence. This may hamper a possible comparison of phenotypic analyses from different laboratories and may explain some conflicting data reported in the literature. However, we believe that our classification of B-CLL cases into phenotypic subsets (as shown, for example, in Table 2 ) reflects true phenotypic differences and that it lends itself to the possibility of clinical correlations provided that cells from all cases are analyzed using the same reagents and the same detection system.
Adhesion molecules of the Ig superfamily (CD54 and CD58) were found in a minority of B-CLL cases. As for other cell types (eg, endothelial cells and keratinocytes), this may reflect a state of cell activation induced by cytokines produced by the malignant B cells or by other cell types. 47 While confirming previous studies describing the expression of PI and p2 integrin chains on B-CLL ce11s,23.42-44 we found that cells from 12 of 74 B-CLL patients also expressed p3 chains, always in association with PI and p2 chains. This novel finding was confirmed by both flow cytometric and For personal use only. on October 23, 2017. by guest www.bloodjournal.org From biochemical analyses and we could rule out that it was due to adherent platelets (see Results). Therefore, we could define distinct groups of patients according to the expression of (3,, Pz, and & integrin chains. No major differences were noted when expression of the above described adhesion molecules was analyzed on B-CLL cells simultaneously obtained from blood and bone marrow or when CD5' clones were compared with CD5-clones, with the exception of a significantly higher incidence of LeuMS clones in the latter group.
The high degree of biologic and clinical heterogeneity of B-CLL has prompted numerous studies aimed at the detection of risk factors. These studies have been addressed both at the definition of phenotypic heterogeneity of B-CLL cells and of several clinical parameters. We selected groups of patients with distinctive adhesion molecule phenotypes. These groups were evaluated in relation to a variety of clinical features. Staging according to Rai and to Binet, LTD, and the bone marrow histologic pattern have been considered important prognostic parameters in survival analyses of B-CLL.35-38 Furthermore, therapy requirement is related to the appearance of negative risk factors and/or to disease progression. Therefore, we considered the need for therapy as a relevant prognostic variable. Evaluation of survival time could not be taken into account because at least one-half of the patients had a follow-up period shorter than 3 years.
The main conclusions that can be drawn from a correlation between adhesion molecule phenotype and clinical features are the following. Patients whose cells do not express integrin p chains (PI, &, and b3) show the most favorable clinical features as compared with the other groups ( Table 2) . Expression of ax& integrin (LeuMS) has allowed for the detection of a B-CLL subset with clinical features similar to those of HCL and of other types of B-CLL lymphoproliferative disorder^.^^,^^,^^ In the 14 LeuMS+ cases of our series, we did not find most of the features described in the above studies. However, patients whose malignant cells expressed LeuM5 differed from LeuMS-cases for a significant incidence of higher lymphocytosis and of therapy requirement (Table  3) . Furthermore, expression of CD58 was detected in cases with higher incidence of splenomegaly and advanced Rail Binet stages. Diffuse bone marrow infiltration was significantly more frequent in patients whose cells expressed CD44high. This is consistent with the finding that CD44 me- 
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For personal use only. on October 23, 2017. by guest www.bloodjournal.org From diates adhesion of maturing B cells to bone marrow stromal cells. 48 Analyses of the relationships of clinical features with cell phenotypes have their major constraint in the long median survival of B-CLL patients. However, LDT and therapy requirement are evidently dynamic variables and will therefore be evaluated in the long run.
